Low dose sulprostone for termination of second and third trimester pregnancies.
OBJECTIVE
The purpose of this study is to assess the effectiveness and safety of sulprostone (nalador) for labour induction in the event of foetal death or foetal malformations.


METHODS
Retrospective analysis of 284 women with intrauterine foetal death (n=137), or foetal abnormalities (n=147), who underwent labour induction with sulprostone in a continuous dose of 1microg/min intravenously.


RESULTS
All but three women had a successful vaginal delivery. The median induction-expulsion interval was significantly shorter (12h) in the foetal death group compared to the foetal malformation group (25h). Two uterine ruptures were recorded, one in a woman with a uterine anomaly, and one in a woman with a previous caesarean section. There were no other complications. Gestational age had a significant influence on spontaneous expulsion of the placenta: before 24 weeks 55%, and after 24 weeks 82% spontaneous expulsion. For the chance of a neonate born with signs of life, parity was the only significant determinant.


CONCLUSIONS
The use of intravenous sulprostone in a low continuous dose is both effective and safe. In addition, this study does not support former opinions that smoking and advanced maternal age are contraindications.
de Boer
M A
MA
Department of Obstetrics, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
van Gemund
N
N
Scherjon
S A
SA
Kanhai
H H
HH
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced; D000013:Congenital Abnormalities; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005865:Gestational Age; D006801:Humans; D007751:Labor, Induced; D016014:Linear Models; D010298:Parity; D006473:Postpartum Hemorrhage / Q000453:epidemiology; D011247:Pregnancy; D012189:Retrospective Studies; D013997:Time Factors; D014597:Uterine Rupture / Q000453:epidemiology; D014599:Uterus / Q000002:abnormalities
D000020:Abortifacient Agents, Nonsteroidal; C016767:sulprostone; D015232:Dinoprostone